Warning: The NCBI web site requires JavaScript to function. more...
Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM.
Breast Cancer Res. 2008;10(4):R70. Epub 2008 Aug 13.
Related citations
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
Breast Cancer Res. 2007;9(4):R50.
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.
Breast Cancer Res. 2005;7(5):R708-18. Epub 2005 Jul 6.
Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion.
Xian W, Rosenberg MP, DiGiovanni J.
Oncogene. 1997 Mar 27;14(12):1435-44.
Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
Cytometry. 2001 Aug 1;44(4):338-48.
Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD.
Mol Cancer Res. 2009 Nov;7(11):1882-92. Epub 2009 Oct 27.
Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K, Bol D, Carbajal S, Beltrán L, Moats S, Chan K, Jorcano J, DiGiovanni J.
Oncogene. 2000 Aug 31;19(37):4243-54.
Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
Mol Cancer Res. 2007 Apr;5(4):393-401.
Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL 3rd.
Cancer Res. 2006 Dec 1;66(23):11279-86.
Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK.
Breast Cancer Res Treat. 2006 Jan;95(1):17-27.
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
Chen X, Yeung TK, Wang Z.
Biochem Biophys Res Commun. 2000 Nov 2;277(3):757-63.
gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
Samant GV, Sylvester PW.
Cell Prolif. 2006 Dec;39(6):563-74.
ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas.
Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ.
J Biol Chem. 2002 Jun 21;277(25):22692-8. Epub 2002 Apr 11.
Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD, Seachrist DD, Montañez-Wiscovich ME, Danielpour D, Keri RA.
Oncogene. 2005 Aug 4;24(33):5173-90.
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD.
Int J Cancer. 2007 May 1;120(9):1874-82.
Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
EMBO J. 1997 Sep 15;16(18):5608-17.
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE.
Breast Cancer Res Treat. 2009 Mar;114(2):263-75. Epub 2008 Apr 14.
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.
Maroulakou IG, Oemler W, Naber SP, Tsichlis PN.
Cancer Res. 2007 Jan 1;67(1):167-77.
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S, Huang X, Lee CK, Liu B.
Oncogene. 2010 Jul 22;29(29):4225-36. Epub 2010 May 24.
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.
Clin Cancer Res. 2006 Jul 1;12(13):4103-11.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on